What is Zacks Research’s Forecast for REVB FY2026 Earnings?

Revelation Biosciences, Inc. (NASDAQ:REVB) – Equities research analysts at Zacks Research increased their FY2026 EPS estimates for shares of Revelation Biosciences in a report issued on Friday, November 6th. Zacks Research analyst B. Sorensen now forecasts that the company will post earnings of ($15.08) per share for the year, up from their prior forecast of ($36.18). The consensus estimate for Revelation Biosciences’ current full-year earnings is ($35.08) per share. Zacks Research also issued estimates for Revelation Biosciences’ Q4 2026 earnings at ($5.58) EPS and FY2027 earnings at ($17.78) EPS.

Separately, Weiss Ratings raised Revelation Biosciences from a “sell (e)” rating to a “sell (e+)” rating in a research note on Tuesday. One analyst has rated the stock with a Sell rating. According to MarketBeat.com, the company has a consensus rating of “Sell”.

Revelation Biosciences Stock Performance

Shares of NASDAQ:REVB opened at $4.38 on Friday. The firm has a fifty day moving average of $5.21 and a 200 day moving average of $7.47. Revelation Biosciences has a 52-week low of $3.08 and a 52-week high of $40.60. The firm has a market capitalization of $2.98 million, a PE ratio of -0.10 and a beta of -0.13.

Revelation Biosciences (NASDAQ:REVB) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($5.92) EPS for the quarter, topping analysts’ consensus estimates of ($6.16) by $0.24.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc. is a clinical-stage biotechnology company focused on developing therapies that stimulate the body’s innate immune system. The company’s research is centered on immunologic treatments intended to help prevent or manage infectious and other acute diseases. Its lead development programs are based on Gemini, a proprietary toll-like receptor 4 agonist designed to activate innate immune responses. Revelation has investigated intranasal formulations, including REVTx-99, for potential use against respiratory viral infections, as well as other candidates aimed at addressing serious medical conditions such as sepsis.